Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

[1]  A. Difeo,et al.  The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. , 2019, Cancer research.

[2]  G. Narla,et al.  Protein phosphatase 2A Aα regulates Aβ protein expression and stability , 2019, The Journal of Biological Chemistry.

[3]  Krister Wennerberg,et al.  PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells , 2018, Science Translational Medicine.

[4]  R. Sears,et al.  Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. , 2018, Cancer research.

[5]  Mehmet Koyutürk,et al.  The KSEA App: a web‐based tool for kinase activity inference from quantitative phosphoproteomics , 2017, Bioinform..

[6]  Hyungwon Choi,et al.  ProHits-viz: a suite of web tools for visualizing interaction proteomics data , 2017, Nature Methods.

[7]  E. Chen,et al.  Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth , 2017, The Journal of clinical investigation.

[8]  M. Chance,et al.  A Targeted Mass Spectrometry Assay for Detection of HIV Gag Protein Following Induction of Latent Viral Reservoirs. , 2017, Analytical chemistry.

[9]  F. Amant,et al.  Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. , 2016, Cancer research.

[10]  G. Mills,et al.  Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway , 2016, Scientific Reports.

[11]  Frank Noé,et al.  HTMD: High-Throughput Molecular Dynamics for Molecular Discovery. , 2016, Journal of chemical theory and computation.

[12]  M. Galsky,et al.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase , 2016, The FEBS journal.

[13]  M. Diekhans,et al.  The ORFeome Collaboration: a genome-scale human ORF-clone resource , 2016, Nature Methods.

[14]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[15]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[16]  E. Lander,et al.  Comprehensive assessment of cancer missense mutation clustering in protein structures , 2015, Proceedings of the National Academy of Sciences.

[17]  Tero Aittokallio,et al.  Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling , 2015, Scientific Reports.

[18]  D. Huntsman,et al.  Targeted mutation analysis of endometrial clear cell carcinoma , 2015, Histopathology.

[19]  Alexander R. Pico,et al.  Affinity purification–mass spectrometry and network analysis to understand protein-protein interactions , 2014, Nature Protocols.

[20]  P. Wolynes,et al.  Complex energy landscape of a giant repeat protein. , 2013, Structure.

[21]  Hannah Gilmore,et al.  Tumor microenvironmental signaling elicits epithelial-mesenchymal plasticity through cooperation with transforming genetic events. , 2013, Neoplasia.

[22]  S. Batra,et al.  Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. , 2013, Cancer letters.

[23]  Amber L. Couzens,et al.  The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.

[24]  S. Joel,et al.  Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.

[25]  H. Katagiri,et al.  PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes. , 2013, Anticancer research.

[26]  James S. Duncan,et al.  Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models , 2012, Clinical Cancer Research.

[27]  Barry R Davies,et al.  Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). , 2012, Cancer research.

[28]  G. Walter,et al.  Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways , 2012, Cell cycle.

[29]  Sumudu P. Leelananda,et al.  The importance of slow motions for protein functional loops , 2012, Physical biology.

[30]  G. Walter,et al.  Human Cancer-Associated Mutations in the Aα Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in Aα Knock-In and Knockout Mice , 2011, Molecular and Cellular Biology.

[31]  M. Jackson,et al.  TGF-β signaling engages an ATM-CHK2-p53–independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells , 2011, Proceedings of the National Academy of Sciences.

[32]  V. Velculescu,et al.  Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. , 2011, The American journal of pathology.

[33]  Wolfgang Huber,et al.  Mapping of signaling networks through synthetic genetic interaction analysis by RNAi , 2011, Nature Methods.

[34]  W. Hahn,et al.  Identification of PP2A complexes and pathways involved in cell transformation. , 2010, Cancer research.

[35]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[36]  Martin Karplus,et al.  PR65, the HEAT-repeat scaffold of phosphatase PP2A, is an elastic connector that links force and catalysis , 2010, Proceedings of the National Academy of Sciences.

[37]  Yigong Shi.  Serine/Threonine Phosphatases: Mechanism through Structure , 2009, Cell.

[38]  Heidi S Feiler,et al.  Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. , 2009, Cancer research.

[39]  Massimiliano Bonomi,et al.  Reconstructing the equilibrium Boltzmann distribution from well‐tempered metadynamics , 2009, J. Comput. Chem..

[40]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[41]  M J Harvey,et al.  ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale. , 2009, Journal of chemical theory and computation.

[42]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[43]  W. Hahn,et al.  The Tumor Suppressor PP2A Aβ Regulates the RalA GTPase , 2007, Cell.

[44]  W. Hahn,et al.  The tumor suppressor PP2A Abeta regulates the RalA GTPase. , 2007, Cell.

[45]  F. Porteu,et al.  B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX‐1 and ERK , 2006, The EMBO journal.

[46]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[47]  W. Hahn,et al.  Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. , 2005, Cancer research.

[48]  Lisa L Gomez,et al.  Critical Role for Protein Phosphatase 2A Heterotrimers in Mammalian Cell Survival* , 2004, Journal of Biological Chemistry.

[49]  D. J. Price,et al.  A modified TIP3P water potential for simulation with Ewald summation. , 2004, The Journal of chemical physics.

[50]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[51]  W. Hahn,et al.  Identification of specific PP2A complexes involved in human cell transformation. , 2004, Cancer cell.

[52]  Huong T. T. Pham,et al.  Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: differences in expression, subunit interaction, and evolution. , 2003, The Biochemical journal.

[53]  Huong T. T. Pham,et al.  Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene , 2001, Oncogene.

[54]  G. Russo,et al.  Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms , 2000, Oncogene.

[55]  G. Russo,et al.  Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. , 2000, Oncogene.

[56]  Brian A. Hemmings,et al.  The Structure of the Protein Phosphatase 2A PR65/A Subunit Reveals the Conformation of Its 15 Tandemly Repeated HEAT Motifs , 1999, Cell.

[57]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[58]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[59]  T. B. Miller,et al.  Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A , 1990, Cell.

[60]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[61]  Huong T. T. Pham,et al.  Characterization of the A α and A β subunit isoforms of protein phosphatase 2 A : differences in expression , subunit interaction , and evolution , 2022 .